{"product_id":"aurobindo-swot-analysis","title":"Aurobindo Pharma  SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAurobindo Pharma combines broad product mix and strong manufacturing scale with expanding specialty and API capabilities, but faces margin pressure from pricing competition, regulatory scrutiny, and RM supply risks. Growth hinges on successful biosimilar launches, geographic diversification, and pipeline execution. Want the full story behind the company’s strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain an editable, investor-ready report and Excel matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Product Portfolio and Global Scale\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurobindo Pharma holds one of the industry’s largest generic portfolios across 15+ therapeutic areas, including CNS, cardiovascular, and anti-retrovirals, with over 2,000 product registrations globally as of 2025. This diversity reduces reliance on any single category and supports stable revenue streams—56% of 2024 revenue came from regulated markets. By 2025 the company ranks top-five in US generic prescriptions by volume, reinforcing scale advantages in procurement and market access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVertical Integration in API Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurobindo Pharma manufactures roughly 60–65% of its Active Pharmaceutical Ingredients (APIs) in-house, giving it strong backward integration that cut COGS and ensured supply security during 2024–25 supply shocks; this reduced raw-material import reliance by ~40% versus FY2021. That control supports higher gross margins—around 34% in FY2024 compared with 28–30% peers—and lowers vendor risk and working-capital volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Presence in the US Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurobindo Pharma holds a strong US position, with US sales ~49% of FY2024 revenue (₹23,400 crore \/ $2.8bn) and top-10 share in several generic classes; it averaged ~40 ANDA filings yearly and had 180+ ANDAs approved by Dec 31, 2024, fueling regular launches. Its established distribution ties and contracts with major buying groups limit revenue volatility and supported a 2024 US generic growth of ~6% vs prior year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eState-of-the-Art Manufacturing Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpaurobindo pharma runs who mhra-approved plants producing high-volume oral solids injectables and complex generics with\u003e45% margin advantage versus peers due to scale and automation investment. Continuous CAPEX of ~INR 6.5 bn in FY2024–25 expanded capacity, keeping COGS among the industry lowest and supporting \u0026gt;20% gross margins in FY2025.\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e14 approved plants (WHO\/USFDA\/MHRA) in 2025\u003c\/li\u003e\n\u003cli\u003eProduct mix: oral solids, injectables, complex generics\u003c\/li\u003e\n\u003cli\u003eCAPEX ~INR 6.5 bn FY2024–25\u003c\/li\u003e\n\u003cli\u003eGross margin \u0026gt;20% FY2025; \u0026gt;45% cost advantage vs peers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/paurobindo\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Revenue Streams\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAurobindo Pharma earns about 25% of revenue from the US but also generates roughly 30% from Europe and 20% from emerging markets, plus a strong antiretroviral (ARV) franchise contributing ~12% of sales in FY2024, which reduces dependence on any single market.\u003c\/p\u003e\n\u003cp\u003eGeographic mix shields Aurobindo from localized downturns or country-specific regulatory shifts; for example, weaker EU pricing would be offset by growth in Africa\/Latin America and ARV demand.\u003c\/p\u003e\n\u003cp\u003eThe multi-market strategy means growth drivers span branded generics, APIs, and ARVs across ~150 countries, lowering regulatory-concentration risk and smoothing cash flow volatility.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% revenue Europe\u003c\/li\u003e\n\u003cli\u003e~20% revenue emerging markets\u003c\/li\u003e\n\u003cli\u003e~12% revenue ARVs\u003c\/li\u003e\n\u003cli\u003ePresence in ~150 countries\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurobindo Pharma: US‑led scale, 2,000+ registrations, 180+ ANDAs, 34% gross margin\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurobindo Pharma has a diversified portfolio (2,000+ registrations, 15+ areas) and strong US scale (49% of FY2024 revenue; 180+ ANDAs by 31‑Dec‑2024), 14 WHO\/USFDA\/MHRA plants (2025), ~60–65% in‑house API production, FY2024 gross margin ~34%, CAPEX ~INR 6.5bn FY2024–25; presence in ~150 countries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistrations\u003c\/td\u003e\n\u003ctd\u003e2,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS rev FY2024\u003c\/td\u003e\n\u003ctd\u003e49%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eANDA approvals\u003c\/td\u003e\n\u003ctd\u003e180+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlants (2025)\u003c\/td\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIn‑house API\u003c\/td\u003e\n\u003ctd\u003e60–65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin FY2024\u003c\/td\u003e\n\u003ctd\u003e~34%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAPEX FY24‑25\u003c\/td\u003e\n\u003ctd\u003eINR 6.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Aurobindo Pharma, outlining its core strengths, operational and regulatory weaknesses, market and product expansion opportunities, and key threats from competition, pricing pressure, and compliance risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT matrix on Aurobindo Pharma for fast, visual strategy alignment, highlighting strengths like broad generics portfolio and cost-efficient manufacturing alongside risks from regulatory scrutiny and pricing pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistory of Regulatory Compliance Issues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAurobindo Pharma has a history of USFDA actions, including multiple Form 483s and at least three Warning Letters since 2016, most recently impacting its Unit IV in 2021 and contributing to a 12% revenue dip in the affected US generics segment in FY2021-22 (₹7.8bn impact estimated by analysts).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Concentration in the US Generic Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite global expansion, about 58% of Aurobindo Pharma’s revenue came from the US generics in FY2024 (FY end Mar 2024), leaving earnings exposed to steep price erosion—US generic price declines hit double digits in many segments in 2023—plus aggressive competition that compressed gross margins to ~28% in FY2024. Heavy US reliance also raises sensitivity to policy changes like Medicare pricing reforms.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Presence in Proprietary Branded Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpaurobindo pharma revenue mix remains skewed: in fy2024 sales of generics constituted about total inr crore leaving limited exposure to high-margin branded drugs.\u003e\n\u003cpthe company has begun biosimilars investment spend rose to inr crore in fy2024 no proprietary blockbusters or late-stage specialty assets limit exponential growth potential.\u003e\n\u003cpthis volume-driven model forces participation in price-led competition gross margins averaged fy2024 below specialty peers keeping aurobindo perpetual generic price wars.\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\u003c\/paurobindo\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Debt Obligations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpaurobindo pharma aggressive m and capex pushed consolidated gross debt to about inr billion million as of march raising interest principal servicing needs that compete with r dividends.\u003e\u003cphigh leverage increases vulnerability to rate hikes bps rise could add million in interest cash for pipeline investment and shareholder returns.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGross debt: INR 28.6 bn (Mar 2025)\u003c\/li\u003e\n\u003cli\u003eInterest sensitivity: ~INR 286 mn per 100 bps\u003c\/li\u003e\n\u003cli\u003eLess cash for R\u0026amp;D\/dividends\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/phigh\u003e\u003c\/paurobindo\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSensitivity to Raw Material Price Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAurobindo’s backward integration reduces but does not eliminate exposure to volatile API input costs; basic chemicals and solvents still caused raw-material cost swings that pressured margins in 2024 when petrochemical-linked prices rose ~12% year-on-year.\u003c\/p\u003e\n\u003cp\u003eRegulatory moves in China and supply-chain shocks (eg. 2023 port delays) can trigger sudden input spikes Aurobindo can’t fully pass on in the low-margin generics market, squeezing EBITDA—reported 2024 adjusted EBITDA margin was ~16.5%.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eBackward integration helps but limits only certain inputs\u003c\/li\u003e\n\u003cli\u003ePetrochemical-linked raw costs rose ~12% in 2024\u003c\/li\u003e\n\u003cli\u003eChina environmental rules and logistics shocks drive sudden spikes\u003c\/li\u003e\n\u003cli\u003eCompetitive generics pricing restrains passing costs—2024 EBITDA ~16.5%\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAurobindo risks: US concentration, recurring FDA hits, low-margin generics, rising debt\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAurobindo’s weaknesses: high US dependence (58% revenue FY2024), recurring USFDA actions (multiple 483s, ≥3 Warning Letters since 2016; Unit IV hit 2021), low-margin, volume-led generics (82% revenue; gross margin ~36% FY2024; adj. EBITDA ~16.5% 2024), rising debt INR 28.6bn (Mar 2025) with ~INR 286mn\/100bps interest sensitivity, limited proprietary specialty\/biosimilar wins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue share\u003c\/td\u003e\n\u003ctd\u003e58% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics share\u003c\/td\u003e\n\u003ctd\u003e82% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e~36% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. EBITDA\u003c\/td\u003e\n\u003ctd\u003e~16.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross debt\u003c\/td\u003e\n\u003ctd\u003eINR 28.6bn (Mar 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInterest sensitivity\u003c\/td\u003e\n\u003ctd\u003eINR 286mn \/100bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAurobindo Pharma  SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is the same editable file included in your download. Buy now to unlock the complete, in-depth Aurobindo Pharma SWOT analysis with strengths, weaknesses, opportunities, and threats fully detailed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752790110585,"sku":"aurobindo-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/aurobindo-swot-analysis.png?v=1772245490","url":"https:\/\/matrixbcg.com\/products\/aurobindo-swot-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}